Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update
November 14, 2024
Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange
November 4, 2024
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity
October 22, 2024
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity
October 21, 2024
Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock
October 4, 2024
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations
October 3, 2024
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Launch of Clinical Study Combining Its Flagship Topical Exosome Skincare Products with a Medical Aesthetic Energy Device
October 2, 2024
Elevai Labs Inc. Announces Pricing of $8.0 Million Public Offering
September 23, 2024
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Results for E-Series Exosome Technology in Potential Melasma Applications
September 10, 2024
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Encouraging Data Results Indicating Potential for Hair Restoration Using Proprietary Exosome Technology
September 3, 2024
Elevai Labs Inc. Files Combination Patents with Yuva Biosciences for Breakthrough Hair and Scalp Care Technology Utilizing YuvaBioⓇ Y100™ Mitochondrial Innovation and Elevai Exosomes™
August 28, 2024
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Data Results with Completion of Clinical Study of Elevai Enfinity™ Topical Exosome Serum
August 26, 2024
Elevai Labs Inc. Subsidiary, Elevai Research Inc., Announces Preliminary Positive Research Data Highlighting the Potential of Proprietary Exosome Technology for Skin Health Applications
August 19, 2024
Elevai Labs Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
August 14, 2024
Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, PhD
July 30, 2024
Elevai Labs Inc. Subsidiary, Elevai Skincare, Announces The Elevai S-Series Hair and Scalp Care Product Line
June 28, 2024
Elevai Labs Inc. Subsidiary, Elevai Skincare to Debut Upcoming New Product Line at The Aesthetic Show 2024
June 26, 2024
Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs
June 14, 2024
Elevai Labs Subsidiary, Elevai Skincare, to Present at the Beauty Through Science Conference in Stockholm
May 29, 2024
Elevai Labs Inc Subsidiary, Elevai Biosciences, to Present at the UCLA LA-BEST 2024 Conference
May 22, 2024
Elevai Labs Inc. Reports First Quarter 2024 Financial Results
May 15, 2024
Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity
May 2, 2024
Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome Skincare
May 1, 2024
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
May 1, 2024
Elevai Labs Highlights Global Distribution Partnership Overview: Contracts May Secure $4.9M Top Line Revenue Commitments
April 29, 2024
ELEVAI Labs Enters the Taiwan Market with Signing of 5th International Distribution Agreement in 14 Months
April 22, 2024
Elevai Labs Inc. Reports Record Full Year 2023 and Fourth Quarter Financial Results
March 29, 2024
Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical Market
March 18, 2024
ELEVAI Labs Inc. Announces Issuance of Patent from U.S. Patent & Trademark Office
January 24, 2024
ELEVAI LABS, Inc. Reports Strong Preliminary Unaudited Financial Performance for Fiscal Year 2023, Highlighting Significant Revenue Growth and Expanding Global Reach
January 17, 2024
ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology
January 16, 2024
ELEVAI LABS, Inc. to Participate in Upcoming Aesthetic Industry Conferences
January 2, 2024
Elevai Labs Inc Announces Financial Results for the Quarter Ended September 30, 2023
December 11, 2023
ELEVAI Labs, Inc. Expands International Distribution into Europe
December 7, 2023
Elevai Labs Enters into Licensing Agreement with Yuva Biosciences to Combine Exosome and Mitochondrial Technologies to Develop New Aesthetics Products
November 29, 2023
Univest Securities, LLC Announces Closing of $6 Million Initial Public Offering of Common Stock for its Client ELEVAI Labs Inc. (Nasdaq: ELAB)
November 24, 2023
ELEVAI Labs, Inc. Announces Closing of $6,000,000 Initial Public Offering
November 24, 2023
ELEVAI Labs Partners with Dmark Multisales Corporation as Exclusive Philippines Distributor
August 1, 2023
ELEVAI Labs Announces New International Distributor Agreement with Central Circle Company in Kuwait Patented Exosome Skincare Line Now Available in the MENA Region
June 8, 2023
ELEVAI LABS AMPLIFIES INTERNATIONAL REACH THROUGH VIET CAN TRADING AND SERVICE CO., LTD. WITH DISTRIBUTION IN VIETNAM
May 18, 2023
ELEVAI Labs Announces Research Grant Award and Partnership to Better Characterize the ’Payload’ of ELEVAI's Stem Cell-derived Exosomes
April 26, 2023
ELEVAI BRINGS PARADIGM-SHIFTING PROCEDURE SKINCARE TO ASLMS Company Unveils Groundbreaking Approach to Pre- and Post-Procedure Skincare
April 5, 2023
ELEVAI LABS EXPANDS INTERNATIONAL REACH WITH INDUSTRY LEADER EVOLVE MEDICAL INC. FOR CANADIAN DISTRIBUTION
February 21, 2023
ELEVAI LABS EXPANDS BOARD OF DIRECTORS WITH THE APPOINTMENT OF GLOBAL AESTHETICS EXECUTIVE CRYSTAL MUILENBURG
February 7, 2023
ELEVAI LABS RETURNS TO INDUSTRY-LEADING OCTANE AESTHETICS TECH FORUM “People’s Choice Award” Winner Presents Groundbreaking Exosome Technology
January 17, 2023
ELEVAI Labs, Inc. expands advisory board with the addition of James R. Headley as Strategic Advisor
November 29, 2022
ELEVAI LABS EXPANDS ADVISORY BOARD WITH THE ADDITION OF JAMES R. HEADLEY AS STRATEGIC ADVISOR
November 29, 2022
ELEVAI Labs, Inc. unveils paradigm shift skincare technology during Global Aesthetics ConferenceELEVAI Labs, Inc. unveils paradigm shift skincare technology during Global Aesthetics Conference
November 1, 2022
ELEVAI Labs, Inc. announces laboratory expansion allowing fivefold increase in product manufacturing capabilities
September 22, 2022
ELEVAI Labs, Inc. Announces appointment of Chris Kraneiss as Chief Commercial Officer
August 17, 2022
ELEVAI Labs, Inc. is pleased to announce the appointment of Brenda Buechler as Chief Marketing and Brand Advisor
April 29, 2022
ELEVAI is pleased to announce it has won the Peoples Choice Award at the 2022 Octane Aesthetics Tech Summit
January 25, 2022
ELEVAI Labs, Inc. Announces Global Distribution Partnership With Premier Aesthetic Device Company Dermapenworld
January 21, 2022
2022 Aesthetics Tech Summit in Newport Beach, California
January 6, 2022
E-SERIES Product Line Launching
December 21, 2021
